双黄连注射剂治疗急性上呼吸道感染的系统评价研究  

Systematic Review of Shuanghuanglian Injection in the Treatment of Acute Upper Respiratory Infection

作　　者：吴嘉瑞[1] 张丹[1] 张晓朦[1] 张冰[1] 

机构地区：[1]北京中医药大学中药学院,北京100102

出　　处：《药物流行病学杂志》2016年第5期269-274,共6页Chinese Journal of Pharmacoepidemiology

基　　金：国家自然科学基金项目(编号:81473547);中华中医药学会立项课题(编号:CACMRE2014-A-03);北京市与中央在京高校共建项目(编号:BJGJ1420)

摘　　要：目的:评价双黄连注射剂治疗急性上呼吸道感染的临床疗效。方法:全面检索中国期刊全文数据库(CNKI)、中国生物医学文献数据库(CBM)、中文科技期刊全文数据库(VIP)、万方数据库、Pub Med、Embase和Cochrane Library数据库有关双黄连注射剂治疗急性上呼吸道感染的随机对照试验或半随机对照试验文献,采用Cochrane风险评价表评价其研究质量,提取资料并通过Rev Man 5.2进行数据分析。结果:系统评价中,符合纳入标准的研究共有21篇,累计受试者2 914例。Meta分析的结果显示:双黄连注射剂治疗急性上呼吸道感染的疗效均优于西医治疗,可有效提高总有效率(RR=1.20,95%CI:[1.16,1.25],P<0.000 1),缩短退热时间、咳嗽持续时间。结论:双黄连注射剂治疗急性上呼吸道感染具有较好的疗效。Objective： To systematically evaluate the clinical efficacy of Shuanghuanglian injection（ SHL） in the treatment of acute upper respiratory infections（ AURI）. Methods： According to the inclusion standard and the elimination standard randomized controlled trials（ RCTs） and quasi-RCTs regarding SHL in the treatment of AURI were collected through comprehensive searches of China National Knowledge Infrastructure（ CNKI）,Chinese Scientific Journals Database（ VIP）,Wanfang Database,Chinese Biomedical Literature Database（ CBM）,Pub Med,Embase and Cochrane Library.Assessed the quality of the included studies by the Cochrane risk of bias,and extracted the information from the included studies. Meta-analysis was conducted with the software Review Manager 5. 2. Results： A total of 21 studies with 2 914 participants were included. The Meta-analysis showed that effect of SHL in the treatment of acute upper respiratory infection were better than western medicine treatment,SHL injection can improve the total clinical efficiency（ RR = 1. 20,95% CI：[1. 16,1. 25],P〈0. 000 1）,shorten the time of fever,cough duration. Conclusion： Shuanghuanglian Injection in the treatment of acute upper respiratory infection had good curative effect.

关 键 词：双黄连注射剂 急性上呼吸道感染 系统评价 

分 类 号：R286[医药卫生—中药学]